Literature DB >> 27572389

Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains.

Mahdi Abastabar1, Nooshin Rahimi2, Jacques F Meis3,4, Narges Aslani2, Sadegh Khodavaisy5, Mojtaba Nabili1, Ali Rezaei-Matehkolaei6, Koichi Makimura7, Hamid Badali8,9.   

Abstract

A collection of azole-susceptible (n = 141) and azole-resistant (n = 27) Aspergillus fumigatus isolates was tested against seven antifungal drugs, including the new imidazoles lanoconazole and luliconazole. The luliconazole and lanoconazole MIC90 values for the azole-susceptible strains were 0.001 μg/ml and 0.008 μg/ml, and those for the azole-resistant strains were 0.016 μg/ml and 0.032 μg/ml.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27572389      PMCID： PMC5075107          DOI： 10.1128/AAC.01193-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses.

Authors:  Hiroyasu Koga; Yuri Tsuji; Kazuyoshi Inoue; Kazuo Kanai; Toshiro Majima; Tatsuya Kasai; Katsuhisa Uchida; Hideyo Yamaguchi
Journal:  J Infect Chemother       Date:  2006-06       Impact factor: 2.211

2.  Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model.

Authors:  M A Ghannoum; L Long; H G Kim; A J Cirino; A R Miller; P Mallefet
Journal:  Med Mycol       Date:  2010-05       Impact factor: 4.076

3.  Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections.

Authors:  Y Niwano; N Kuzuhara; Y Goto; Y Munechika; H Kodama; K Kanai; M Yoshida; T Miyazaki; H Yamaguchi
Journal:  Int J Antimicrob Agents       Date:  1999-08       Impact factor: 5.283

4.  Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study.

Authors:  Michael Jarratt; Terry Jones; Steven Kempers; Phoebe Rich; Katy Morton; Norifumi Nakamura; Amir Tavakkol
Journal:  Cutis       Date:  2013-04

5.  In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent.

Authors:  Katsuhisa Uchida; Yayoi Nishiyama; Hideyo Yamaguchi
Journal:  J Infect Chemother       Date:  2004-08       Impact factor: 2.211

6.  In vitro antifungal activities of luliconazole, a new topical imidazole.

Authors:  Hiroyasu Koga; Yasuko Nanjoh; Koichi Makimura; Ryoji Tsuboi
Journal:  Med Mycol       Date:  2009       Impact factor: 4.076

7.  Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran.

Authors:  Hamid Badali; Afsane Vaezi; Iman Haghani; Seyed A Yazdanparast; Mohammad T Hedayati; Bita Mousavi; Saham Ansari; Ferry Hagen; Jacques F Meis; Anuradha Chowdhary
Journal:  Mycoses       Date:  2013-05-14       Impact factor: 4.377

8.  Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.

Authors:  Werner J Heinz; Gerlinde Egerer; Heinrich Lellek; Angelika Boehme; Jochen Greiner
Journal:  Mycoses       Date:  2012-11-21       Impact factor: 4.377

9.  Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.

Authors:  Jan W M van der Linden; Eveline Snelders; Greetje A Kampinga; Bart J A Rijnders; Eva Mattsson; Yvette J Debets-Ossenkopp; Ed J Kuijper; Frank H Van Tiel; Willem J G Melchers; Paul E Verweij
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

Review 10.  Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Jianping Xu; Jacques F Meis
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823
View more
  15 in total

1.  In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.

Authors:  Gholam Reza Shokoohi; Hamid Badali; Hossein Mirhendi; Saham Ansari; Ali Rezaei-Matehkolaei; Bahram Ahmadi; Afsane Vaezi; Mohamed Mahdi Alshahni; Koichi Makimura
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Somayeh Roodgari; Mojtaba Taghizadeh Armaki; Mohammad Taghi Hedayati; Tahereh Shokohi; Iman Haghani; Javad Javidnia; Firoozeh Kermani; Hamid Badali; Mahdi Abastabar
Journal:  Mycopathologia       Date:  2021-03-15       Impact factor: 2.574

3.  Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.

Authors:  Mahdi Abastabar; Abdullah M S Al-Hatmi; Mohammad Vafaei Moghaddam; G Sybren de Hoog; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Roshanak Daie Ghazvini; Reza Kachuei; Ali Rezaei-Matehkolaei; Koichi Makimura; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates.

Authors:  Ali Rezaei-Matehkolaei; Sadegh Khodavaisy; Mohamad Mahdi Alshahni; Takashi Tamura; Kazuo Satoh; Mahdi Abastabar; Gholam Reza Shokoohi; Bahram Ahmadi; Mohammad Kord; Simin Taghipour; Koichi Makimura; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Molecular identification, biofilm formation and antifungal susceptibility of Rhodotorula spp.

Authors:  Maral Gharaghani; Simin Taghipour; Ali Zarei Mahmoudabadi
Journal:  Mol Biol Rep       Date:  2020-11-01       Impact factor: 2.316

6.  Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates.

Authors:  Zahra Taheri Rizi; Mahdi Abastabar; Hamed Fakhim; Macit Ilkit; Fatemeh Ahangarkani; Javad Javidnia; Iman Haghani; Jacques F Meis; Hamid Badali
Journal:  Mycopathologia       Date:  2020-02-28       Impact factor: 2.574

7.  Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.

Authors:  Mahdi Abastabar; Iman Haghani; Tahereh Shokohi; Mohammad Taghi Hedayati; Seyed Reza Aghili; Ali Jedi; Sulmaz Dadashi; Shafigheh Shabanzadeh; Tahereh Hosseini; Narges Aslani; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

8.  Genotypic diversity of Iranian Cryptococcus neoformans using multilocus sequence typing (MLST) and susceptibility to antifungals.

Authors:  Maryam Moslem; Mahnaz Fatahinia; Neda Kiasat; Ali Zarei Mahmoudabadi
Journal:  Mol Biol Rep       Date:  2021-05-31       Impact factor: 2.316

9.  cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex.

Authors:  Vanessa R Barrs; Jos Houbraken; Jessica J Talbot; Jens C Frisvad; Jacques F Meis; Ferry Hagen; Paul E Verweij; David E Hibbs; Felcia Lai; Paul W Groundwater; Robert A Samson; Sarah E Kidd
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

10.  The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains.

Authors:  Maryam Moslem; Ali Zarei Mahmoudabadi
Journal:  Iran J Microbiol       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.